DABIGATRAN ETEXILATE MESYLATE Drug Interactions
Also known as: Pradaxa
Dabigatran (Pradaxa) is a medication that helps prevent blood clots from forming in your body. It works by directly blocking a substance called thrombin, which is essential for blood clotting. This medicine is primarily used to reduce the risk of stroke in people with a type of irregular heartbeat called atrial fibrillation, and to treat or prevent deep vein clots (DVT) and lung clots (PE) in certain situations.DABIGATRAN ETEXILATE MESYLATE has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen, an NSAID, with dabigatran, an anticoagulant, significantly increases the risk of serious bleeding, including internal bleeding. This combination should generally be avoided.
Mechanism
Naproxen inhibits cyclooxygenase (COX-1 and COX-2), leading to reduced prostaglandin synthesis, which impairs gastric mucosal protection and inhibits platelet aggregation. Dabigatran directly inhibits thrombin, preventing clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
Patients are at a substantially increased risk for major bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other site-specific bleeding. The risk of gastrointestinal bleeding can be 3-5 times higher compared to dabigatran alone, with potential for life-threatening outcomes. This combination should be avoided due to the high risk of bleeding. If an analgesic is required, consider acetaminophen as a safer alternative. If NSAID use is absolutely necessary, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding. Proton pump inhibitor co-therapy may reduce GI bleeding risk but does not eliminate it.
Combining etodolac with dabigatran significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Etodolac, an NSAID, inhibits prostaglandin synthesis, which reduces platelet aggregation and impairs gastrointestinal mucosal protection. Dabigatran, a direct thrombin inhibitor, prevents clot formation. The combined antiplatelet and anticoagulant effects lead to an additive increase in bleeding risk.
Clinical Management
Patients are at a substantially increased risk of serious bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, or other major bleeding events. The risk of major bleeding can be several-fold higher compared to dabigatran alone. This combination should generally be avoided due to the high bleeding risk. If pain relief is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely essential, use the lowest effective dose for the shortest possible duration, and monitor closely for signs of bleeding. Proton pump inhibitors may be considered for gastrointestinal protection.
Combining aspirin with dabigatran significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided unless specifically recommended and closely monitored by your doctor.
Mechanism
Aspirin, even at low doses, inhibits platelet aggregation through irreversible cyclooxygenase-1 (COX-1) inhibition, reducing the blood's ability to clot. Dabigatran directly inhibits thrombin, a key enzyme in the coagulation cascade, also preventing clot formation. The concurrent use of these agents results in an additive antiplatelet and anticoagulant effect, leading to a substantially increased risk of bleeding.
Clinical Management
The primary clinical effect is a heightened risk of bleeding, which can manifest as bruising, nosebleeds, gum bleeding, or more severe events like gastrointestinal bleeding, intracranial hemorrhage, or hematuria. The risk of major bleeding with this combination is significantly elevated compared to either drug alone, potentially increasing 2 to 3-fold. This combination should generally be avoided due to the high bleeding risk. If concurrent use is deemed absolutely necessary (e.g., for specific cardiovascular indications), it must be done under strict medical supervision with careful monitoring for bleeding signs and symptoms. Consider alternative antiplatelet agents if aspirin is not essential, or evaluate if the dabigatran dose can be adjusted. Patient education on bleeding precautions is crucial.
Combining ibuprofen with dabigatran significantly increases your risk of serious bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Dabigatran is a direct thrombin inhibitor that prevents the formation of blood clots. The concurrent use of these agents results in an additive antiplatelet and anticoagulant effect, significantly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or even life-threatening. Studies show that co-administration of NSAIDs with DOACs can increase the risk of major bleeding events by 2 to 3-fold compared to DOACs alone. This combination should be avoided if possible. If pain relief is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is deemed essential, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising). Consider gastroprotective agents (e.g., proton pump inhibitors) if NSAID use is unavoidable.
Combining indomethacin with dabigatran significantly increases your risk of serious bleeding, including bleeding in the stomach or intestines. This combination should generally be avoided due to the heightened danger.
Mechanism
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Dabigatran is a direct thrombin inhibitor, preventing clot formation by interfering with the coagulation cascade. The concurrent use results in additive antiplatelet and anticoagulant effects, severely compromising hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., ulcers, melena, hematemesis), intracranial hemorrhage, hematuria, or other forms of internal or external bleeding. This combined risk is significantly higher than with either drug alone, potentially leading to severe, life-threatening hemorrhagic events. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies or a different type of analgesic with a lower bleeding risk. If concurrent use is unavoidable, close monitoring for signs and symptoms of bleeding is imperative, and the lowest effective doses for the shortest duration should be used. Proton pump inhibitor co-therapy may be considered to reduce GI bleeding risk.
Combining celecoxib with dabigatran significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to the serious bleeding potential.
Mechanism
Celecoxib, a COX-2 selective NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal defense and platelet function (to a lesser extent than non-selective NSAIDs). Dabigatran is a direct thrombin inhibitor, which prevents clot formation. Their combined effect leads to an additive increase in bleeding risk by affecting both primary hemostasis and the coagulation cascade.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, including gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis), intracranial hemorrhage, and other serious bleeding events. The risk of major gastrointestinal bleeding can be substantially elevated compared to either drug alone. This combination should generally be avoided. If concurrent therapy is absolutely necessary, use the lowest effective dose of celecoxib for the shortest possible duration, and consider gastroprotective agents (e.g., proton pump inhibitors). Closely monitor for signs and symptoms of bleeding, and regularly assess hemoglobin and hematocrit levels. Alternative pain management strategies that do not increase bleeding risk should be explored.
Combining piroxicam with dabigatran significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor will likely recommend avoiding this combination.
Mechanism
Piroxicam, an NSAID, inhibits prostaglandin synthesis, which impairs platelet aggregation and damages the gastrointestinal mucosa. Dabigatran directly inhibits thrombin, preventing clot formation. The combination leads to additive antiplatelet and anticoagulant effects, alongside increased GI mucosal vulnerability.
Clinical Management
This interaction substantially increases the risk of major bleeding events, particularly gastrointestinal bleeding, which can be life-threatening. Studies show a significantly elevated risk of GI bleeding (e.g., 2-4 fold increase) when NSAIDs are co-administered with DOACs compared to DOACs alone. This combination should generally be avoided due to the high risk of severe bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (like celecoxib) with extreme caution, proton pump inhibitor co-therapy, and close monitoring for bleeding. Discuss alternatives with your healthcare provider.
Combining meloxicam with dabigatran significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Dabigatran is a direct thrombin inhibitor, preventing clot formation. The concurrent use of these agents leads to additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage from the NSAID.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding, which can be life-threatening. Studies show that combining NSAIDs with DOACs like dabigatran can increase the risk of major bleeding by 2 to 3 times compared to dabigatran alone. Other bleeding sites include intracranial hemorrhage, genitourinary, and epistaxis. Avoid concurrent use of meloxicam and dabigatran if possible. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course with close monitoring for bleeding signs and symptoms. Proton pump inhibitors (PPIs) may be considered for gastrointestinal protection if the combination cannot be avoided, but this does not eliminate the increased bleeding risk. Regular monitoring for signs of bleeding (e.g., black tarry stools, unusual bruising, blood in urine) is crucial.
Combining diclofenac, an anti-inflammatory pain reliever, with dabigatran, a blood thinner, significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor will likely avoid this combination.
Mechanism
Diclofenac inhibits prostaglandin synthesis, reducing gastric mucosal protection and impairing platelet function. Dabigatran directly inhibits thrombin, preventing clot formation. The combination leads to additive antiplatelet effects and increased gastrointestinal mucosal damage, synergistically elevating bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can manifest as melena, hematemesis, or severe anemia. Other bleeding events like intracranial hemorrhage or hematuria are also elevated. The risk of serious GI bleeding with NSAIDs and anticoagulants can be 3-15 times higher than with anticoagulants alone. This combination should generally be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternatives with lower GI risk (e.g., acetaminophen) or a COX-2 selective NSAID with concomitant proton pump inhibitor therapy, under close medical supervision. Monitor for signs and symptoms of bleeding.
Combining ketorolac, an NSAID, with dabigatran, a blood thinner, significantly increases your risk of serious bleeding, including in the stomach or intestines. This combination should generally be avoided.
Mechanism
Ketorolac inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which impairs platelet aggregation and damages the gastrointestinal mucosa. Dabigatran directly inhibits thrombin, preventing clot formation. The concurrent use of both drugs results in an additive antiplatelet effect from ketorolac and an anticoagulant effect from dabigatran, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also epistaxis, hematuria, and bruising. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2-3 fold compared to DOACs alone, with GI bleeding being the most common and serious manifestation. This combination should be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative analgesics such as acetaminophen. If no alternative is feasible and the NSAID is short-term, close monitoring for signs of bleeding (e.g., black stools, easy bruising, unusual fatigue) is crucial, and the lowest effective dose for the shortest duration should be used. Proton pump inhibitor co-therapy may reduce GI bleeding risk but does not eliminate it.
For complete prescribing information:
View full DABIGATRAN ETEXILATE MESYLATE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.